Albany, New York, April 24, 2015 : Market Research Reports Search Engine
(MRRSE) has announced the addition of the ‘ Frontier Pharma: Parkinsons Disease -
Identifying and Commercializing First-in-Class Innovation’
report by Market Research Report Search
Engine (MRRSE) to its rapidly growing market research report database. The
report discusses more than 300 therapies for Parkinson’s disease in the
pipeline, including over 90 first-in-class therapies. The report segments the
pipeline products by phase, molecule type, and therapeutic target.
The report describes the key fact that the mechanism of action
of most current and pipeline therapies for Parkinson’s disease is different:
most current therapies focus on neuromodulatory receptors, whereas a majority
of pipeline products act in a neuroprotective fashion, targeting and
eliminating dysfunctional disease processes.
The report presents the clinical and commercial landscape of
Parkinson’s disease, in order to deliver a clear view of the therapeutics and
how they would affect the global scenario. It examines the genetic and
environmental causes of Parkinson’s disease and discusses the pathophysiology
of the disease.
The report details the Parkinson’s
disease therapeutics market’s competitive
landscape as one virtually foreign to consolidation. Of the many Parkinson’s
disease therapeutics brought into the market since 2006, only nine have been
developed in a collaborative effort. This is presented as a major growth
opportunity for market players in the Parkinson’s disease therapeutics market,
as collaboration will aid the scientific aspect of the research, helping the
companies achieve more precise conclusions.
Apart from collaboration, consistent innovation is presented as
a major factor that will aid competitors gain an edge in the highly fragmented
market for Parkinson’s disease therapeutics. Like any field in medicine,
innovation is the one sure way of advancing ahead of competitors on the back of
stronger therapeutics with a more effective and more precise action. The
innovation of biologic therapeutics, in particular, will be an attractive
investment options, as it is a promising field and is supported by financial
support from governments.
Among pipeline products, the report particularly details
pipeline programs targeting the following factors: LRRK2, progranulin, glial
cell-derived neurotrophic factor, cerebral dopamine neurotrophic factor,
tyrosine receptor kinase B, mesencephalic astrocyte-derived neurotrophic
factor, metabotropic glutamate receptor, DJ-1, C-jun-N-terminal kinases,
reactive oxygen species, heat shock proteins, heat shock transcription factor,
growth hormone secretagogue receptor, protein phosphasate 2A, and cytochrome
P450 2D6.
Compiled by experienced industry experts, the report includes
primary and secondary information detailing the trajectory of the market for
Parkinson’s disease therapeutics and includes insightful inputs from leading
experts.
Send An
Enquiry : http://www.mrrse.com/enquiry/131
Table
of Contents
1
Table of Contents 2
1.1 List of Tables 3
1.2 List of Figures 3
2
Executive Summary 5
2.1 Highly Innovative
and Diverse Pipeline 5
2.2 Alignment of
Innovation to Disease Processes and Genetics 5
2.3 Deals Landscape
Present Substantial Investment Opportunities 5
3
The Case for Innovation 6
3.1 Growing
Opportunities for Biologic Products 7
3.2 Diversification of
Molecular Targets 7
3.3 Innovative
First-in-Class Product Developments Remain Attractive 7
3.4 Regulatory and
Reimbursement Policy Shifts Favor First-in-Class Product Innovation 8
3.5 Sustained
Innovation 8
3.6 GBI Research
Report Guidance 9
4
Clinical and Commercial Landscape 10
4.1 Epidemiology 10
4.2 Disease Etiology
11
4.2.1 Exposure to
Environmental Toxins 11
4.2.2 Genetic Causes
of Familial Parkinson’s Disease 11
4.2.3 Susceptibility
Genes for Parkinson’s Disease 13
4.3 Disease
Pathophysiology 13
4.3.1 Basal Ganglia
Anatomy and Physiology 13
4.3.2 Processes
Underlying Neurodegeneration in Parkinson’s Disease 16
4.4 Disease Symptoms
20
4.5 Co-morbidities and
Complications 20
4.6 Diagnosis 21
4.6.1 Classification
21
4.7 Prognosis and
Disease Staging 23
4.8 Treatment Options
24
4.8.1 Pharmacological
Treatment 24
4.8.2
Non-pharmacological Treatments 28
4.9 Marketed Product
Overview 28
4.10 Overview of
Marketed Products for Parkinson’s Disease 29
4.11 Efficacy and
Safety of Marketed Products 31
4.12 Treatment
Algorithm 33
4.13 Current Unmet
Needs 35
5
Assessment of Pipeline Product Innovation 37
5.1 Parkinson’s Disease
Pipeline by Molecule Type, Phase and Therapeutic Targets 37
5.2 Comparative
Distribution of Programs between the Parkinson’s Disease Market and Pipeline by
Therapeutic Target Family 41
6
Signaling Network, Parkinson’s Disease Genetics and Innovation Alignment 46
6.1 The Complexity of
Signaling Network in Central Nervous System 46
6.2 Signaling
Pathways, Disease-Causing Mutations and First-in-Class Molecular Target
Integration 47
6.3 First-in-Class
Target Matrix Assessment 51
7
First-in-Class Target and Pipeline Program Evaluation 54
7.1 Overview of
Pipeline Programs Targeting ?-synuclein 54
7.2 Overview of
Pipeline Programs Targeting LRRK2 57
7.3 Overview of
Pipeline Programs Targeting Glial Cell-Derived Neurotrophic Factor 60
7.4 Overview of
Pipeline Programs Targeting Progranulin 63
7.5 Overview of
Pipeline Programs Targeting Cerebral Dopamine Neurotrophic Factor 66
7.6 Overview of
Pipeline Programs Targeting Mesencephalic Astrocyte-Derived Neurotrophic Factor
68
7.7 Overview of
Pipeline Programs Targeting Tyrosine Receptor Kinase B 70
7.8 Overview of
Pipeline Programs Targeting Metabotropic Glutamate Receptor 4 73
7.9 Overview of
Pipeline Programs Targeting Metabotropic Glutamate Receptor 8 75
7.10 Overview of
Pipeline Programs Targeting C-jun-N-Terminal Kinases 76
7.11 Overview of
Pipeline Programs Targeting DJ-1 79
7.12 Overview of
Pipeline Programs Targeting Reactive Oxygen Species 80
7.13 Overview of
Pipeline Programs Targeting Heat Shock Transcription Factor 1 82
7.14 Overview of
Pipeline Programs Targeting Heat Shock Protein 90 84
7.15 Overview of
Pipeline Programs Targeting Growth Hormone Secretagogue Receptor 86
7.16 Overview of
Pipeline Programs Targeting Protein Phosphatase 2A 88
7.17 Overview of
Pipeline Programs Targeting Cytochrome P450 2D6 90
7.18 Conclusion 91
8
Deals and Strategic Consolidations 93
8.1 Industry-wide
First-in-Class Deals 93
8.2 Parkinson’s
Disease Deals Landscape 95
8.3 Licensing Deals 95
8.3.1 Molecule Type 97
8.3.2 Mechanism of
Action 97
8.4 Co-development
Deals 100
8.4.1 Mechanism of
Action 101
8.5 First-in-Class
Programs Not Involved in Licensing or Co-Development Deals 103
9
Appendix 106
9.1 Abbreviations 106
9.2 References 108
9.3 Contact Us 121
9.4 Disclaimer 121
About Us
Market Research Reports Search Engine (MRRSE) is an
industry-leading database of market intelligence reports. Headquartered in New
York, U.S., MRRSE is driven by a stellar team of research experts and advisors
trained to offer objective advice. Our sophisticated search algorithm returns
results based on the report title, geographical region, publisher, or other
keywords.
MRRSE partners exclusively with leading global publishers to
provide clients single-point access to top-of-the-line market research. MRRSE’s
repository is updated every day to keep its clients ahead of the next new trend
in market research, be it competitive intelligence, product or service trends
or strategic consulting.
Contact
Us:
State
Tower,
90
State Street,
Suite
700,
Albany
NY - 12207
United
States
Tel:
+1-518-618-1030
Email:
sales@mrrse.com
Website:
http://www.mrrse.com/
Blog: http://mrrse.blogspot.com/ 